Theramir Secures €525,000 To Propel Cancer Therapy To Clinical Phase

In a significant boost to its pioneering cancer treatment research, Theramir has successfully raised €525,000 in a bridge funding round. This capital injection is poised to support the company’s operations through the latter half of 2025, targeting a critical milestone: the initiation of clinical trials for their innovative therapy, EVmiR.

EVmiR, now patented by the European Patent Office, represents a novel approach in cancer treatment. By utilising extracellular vesicles (EVs) to deliver microRNAs (miRNAs) directly into tumours, Theramir aims to target oncoproteins—key regulators of cancer cell growth. This precision method promises fewer side effects compared to traditional treatments such as chemotherapy. The company’s technology has demonstrated efficacy in treating metastatic breast cancer and is now being tested for pancreatic and bladder cancers.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Theramir, co-founded by Marianna Prokopi-Demetriades and Costas Pitsillides in 2016, emerged from a passionate pursuit to find a cure for cancer. Their unique technology capitalises on EVs’ natural ability to transport biological information, essentially turning them into couriers that deliver tumour-suppressive messages via miRNAs. This method requires a detailed genetic profile of the patient to enhance the therapy’s precision and effectiveness, potentially offering prophylactic benefits by identifying genetic markers linked to high-risk conditions.

The latest funding round saw participation from notable investors, including Yannos Palate, a former executive at Eli Lilly, who will join Theramir’s advisory board. His extensive experience in life sciences and pharmaceutical engagement is expected to be instrumental in forging strategic partnerships with major pharmaceutical companies. Other investors include Nicosia-based family office Exerte Partners and finance and corporate lawyer Nancy Erotocritou.

Despite the challenges posed by the limited local life-sciences ecosystem in Cyprus, Theramir has managed to attract significant investor interest, raising €2.5 million in total, including €300,000 in grants. The company’s innovative approach and lower research costs compared to major biotech hubs like Boston or London have contributed to its success.

Looking ahead, Theramir is actively seeking a licensing deal with a major pharmaceutical firm to support the clinical trials, which could span up to seven years. The co-founders are optimistic about expediting the timeline through process efficiencies, projecting a market-ready therapy by 2030. In the interim, they are also exploring new revenue streams, such as using EVmiR to treat chronic malignant wounds through a project named MIRACULOUS, which has secured additional funding.

The Future Forbes Realty Global Properties

Cyprus Ranks Among The EU’s Fastest-Growing Populations In 2025

by THEFUTURE.TEAM

July 22, 2026

Cyprus Emerges As A Demographic Outlier In Europe

Cyprus recorded one of the fastest-growing populations in the European Union in 2025, according to the latest Eurostat data. With population growth of 13.7 per 1,000 inhabitants, the island ranked second among the bloc’s 27 member states, behind only Malta (24.1) and ahead of Luxembourg (13.1).

The figures set Cyprus apart at a time when much of Europe is facing ageing populations, declining birth rates and mounting labour shortages.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

A Different Demographic Story

Population growth across the EU remained modest in 2025, increasing by just 1.6 per 1,000 people. The picture, however, was far from uniform. Sixteen member states recorded population gains, while eleven experienced declines.

Malta, Cyprus and Luxembourg posted the strongest growth rates, while Latvia (-8.3), Estonia (-6.8) and Hungary (-5.4) recorded the steepest population losses.

As of January 1, 2026, Cyprus had a population of 996,600. While one of the EU’s smallest member states, it continues to outperform many larger economies on demographic growth.

Growth Driven By Births And Migration

Cyprus stands out because its population is expanding through both natural increase and migration, a combination that has become increasingly uncommon across Europe.

The country was one of only six EU member states where births exceeded deaths in 2025, joining Denmark, Ireland, Luxembourg, Malta and Sweden. Across the EU as a whole, the opposite was true: 4.81 million deaths were recorded against 3.46 million births, leaving the bloc with a natural population decline of roughly 1.35 million people.

Migration more than compensated for that shortfall. Net migration added around 2.05 million people across the EU in 2025, reinforcing its role as the bloc’s primary source of population growth.

Cyprus ranked among the strongest performers here as well. Net migration reached 11.3 people per 1,000 inhabitants, trailing only Malta (23.9) and Spain (11.8).

Why The Numbers Matter

Demographic trends increasingly shape economic performance. Population growth influences labour supply, consumer demand and the long-term sustainability of pension systems and public finances.

For most European countries, migration has become essential to offset declining birth rates. Cyprus is unusual because it combines strong inward migration with positive natural population growth, giving it a demographic profile that few EU members currently share.

Whether that advantage translates into stronger long-term economic performance will depend on how effectively the country integrates new residents, expands its workforce and converts population growth into higher productivity.

As Europe searches for ways to sustain growth despite an ageing population, Cyprus offers an early example of how demographic resilience can become an economic advantage.

Breaking news